lapatinib

Also known as LAP016, FMM, GW 572016, GW572016, N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine

Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).

Key facts

Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 462089041
Drug.image: Lapatinib.svg
Drug.image_class: skin-invert-image
Drug.width: 275
Drug.tradename: Tykerb, Tyverb, others
Drug.MedlinePlus: a607055
Drug.DailyMedID: Lapatinib
Drug.pregnancy_AU: C
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: L01
Drug.ATC_suffix: EH01
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_UK: POM
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only

via Wikipedia infobox

Research

3,736 papers

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.Scientific reports · 2022
Lapatinib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2018
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.Cancer letters · 2024
Lapatinib in breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2007
Lapatinib side-effect management.Clinical journal of oncology nursing · 2010

via PubMed

Wikidata facts

Mass: 580.135

Show 4 more facts

chemical formula: C₂₉H₂₆ClFN₄O₄S
Commons category: Lapatinib
World Health Organisation international non-proprietary name: lapatinib
canonical SMILES: CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

Sources (6)

via Wikidata · CC0

~6 min read

Article

9 sections

Contents

Status
Mode of action
Biochemistry
Clinical application
Breast cancer
Adverse effects
Ongoing trials in gastric cancer
References
External links

==Status== In March 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda). In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated (in combination with letrozole).